Creeping Eruption Treated With Thiabendazole

Publisher Website
Google Scholar
Abstract
Members of the Jacksonville Dermatology Society have treated 51 patients with active creeping eruption with oral thiabendazole. No single- or double-blind placebo controls were used. There were no severe toxic reactions from the drug in the dosage of 25 mg/kg of body weight twice a day. Observation during the patients' hospitalization and results of their laboratory tests lead us to believe that thiabendazole is a relatively safe drug and might be given without hospitalization of the patient. Our results to date have been encouraging for a disease that hitherto has had no satisfactory treatment. Even the seven cases that did not respond entirely received no less than a "good" rating by both doctor and patient. The posttreatment follow-up ranged from one week to one month. During this time none of 44 responsive patients developed relapses of their disease. In our program 25 mg/kg of body weight for 3 to 4 days seems the best treatment schedule.

This publication has 0 references indexed in Scilit: